Medical Foods for Inborn Errors of Metabolism Market Increasing Incidences of Inborn Errors of Metabolism
21 Jun 2021
The medical foods for inborn errors of metabolism market are anticipated to reach US$ 5,768.79 million by 2027 from US$ 2,507.80 million in 2019. The market is projected to grow with a CAGR of 11.2% from 2020 to 2027.
Medical food is the specialized food formulated to be consumed under physician supervision and intended for specific dietary management of a particular disease or condition. These medical conditions usually have distinctive nutritional requirements based on scientific and recognized principles that are established by medical evaluation. The medical food differs from drugs; however, they are intended for consumption under the medical supervision as a primary intervention. When infants are identified with inborn errors of metabolism, they are usually prescribed a special diet suitable for their particular condition that must be followed for the lifetime.
Download sample PDF Copy at:
Company Profiles of Medical Foods for Inborn Errors of Metabolism Market
Nestlé
Abbott
Reckitt Benckiser Group Plc
Ajinomoto Co. Inc.
Solace Nutrition
Primus Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc.
Danone SA
Galen Limited
PKU-MDMIL
Increasing Incidences of Inborn Errors of Metabolism
Inborn errors of metabolism refer to inherited disorders due to mutation in genes coding for proteins functioning in metabolism. The inborn errors of metabolism are a heterogeneous group of disorders and are likely to be inherited through spontaneous mutation. The diseases usually involve failure of metabolic pathways that are either involved in breakdown or storage of biomolecules, such as carbohydrates, proteins, and fatty acids. According to the survey report published by St. Luke's University Health Network in May 2020, inborn errors occur in one among 2,500 births making them significantly common.
A few commonly occurring inborn errors of metabolism include phenylketonuria (PKU), maple syrup urine disease, galactosemia, and fructose intolerance. According to the National Organization for Rare Diseases (NORD), PKU is an inborn error of metabolism that is detectable during the first days of life through newborn screening. The reported incidence of PKU from various newborn-screening programs ranges from one in 13,000 to 19,000 births in the US. The disease is known to affect people majorly from the ethnic backgrounds. Furthermore, according to the US National Library of Medicine (NLM), maple syrup urine disease affects ~1 in 185,000 infants across the world. The NLM also states that the disorder occurs frequently among the old order mennonite population, with an approximate incidence of about one in 380 newborns, which is significantly high.
A few commonly occurring inborn errors of metabolism include homocystinurea, which is an inherited disease that makes the body unable to process certain amino acids properly. According to the NORD, the frequency of homocystinurea in general population is one in 344,000. The prevalence of the disease in Ireland was estimated to be one in 65,000, and in Germany it was estimated to be one in 17,500. Medical foods for inborn errors of metabolism act as nutritional treatment for patients with limited or compromised capacity to ingest, digest, absorb, or metabolize ordinary foods or nutrients. Thus, the increasing incidence of these diseases worldwide is expected to augment the demand for medical foods for inborn errors of metabolism, thereby supporting the market growth.
Product-Based Market Insights
Based on product, the medical foods for inborn errors of metabolism market is segmented into amino acid, glytactin with GMP, amino acid-modified infant formula with iron, low-calcium/vitamin D-free infant formula with iron, low protein food, and others. In 2019, the amino acid segment accounted for the largest share of the global medical foods for inborn errors of metabolism market. The growth of the segment attributes to large number of amino acid based product availability in the market. Furthermore, the number of patients suffering from amino acid disorders is also significantly higher leading to rising demand for these products during the forecast period.
Based on disease, the global medical foods for inborn errors of metabolism market is segmented into phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystonuria, urea cycle disorders, methylmelonic academia, organic acidureas, propionic academia, isovaleric academia, disorders of leucine metabolism, glutaric academia type-1, renal disease, tyrosinemia types I and II, and others. In 2019, the phenylketonuria segment held the largest share of the market; however, the glutaric academia type-1 segment is expected to grow at a fastest rate during the forecast period.
Buy Complete Report of Medical Foods for Inborn Errors of Metabolism Market Study at:
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
E-mail: sam@theinsightpartners.com
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.